Navigation Links
Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
Date:10/15/2010

rogression for Teriflunomide 14mg

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study, both doses of teriflunomide (7 and 14mg) significantly reduced annualized relapse rate (primary study endpoint) by 31% vs. placebo (p is less than or equal to 0.0005). The risk of disability progression (sustained for 12 weeks) was also significantly reduced by 30% for the 14mg dose (p=0.02) and numerically reduced by 24% for the 7mg dose (p=0.08). Both doses of teriflunomide were well tolerated with a similar number of patients reporting either treatment-emergent adverse events (TEAEs) including serious adverse events or TEAEs leading to treatment discontinuation in the treatment vs. placebo arms.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/players/English/46556-Sanofi-Aventis-Teriflunomide/

"We are very pleased with the successful results of the TEMSO study which are an important step forward in multiple sclerosis clinical research," said Marc Cluzel, M.D., Ph.D., Executive Vice President, Research & Development, sanofi-aventis. "These exciting results with teriflunomide represent a new real hope to delivering an oral therapy to patients who live with this serious condition and are eager for new treatment options, and more convenient product forms in-line with our sanofi-aventis commitment to multiple sclerosis."

The results of the TEMSO trial are the first study findings from a large phase III clinical development program on teriflunomide. These results were presented today during the European Committee for Treatment and Research in M
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Medisafe 1 Technologies Successfully Tests Prototype of Patented Syringe Locking Device
2. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals
3. Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System
4. Omeros Successfully Unlocks Orphan GPCRs
5. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
6. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
7. MedAvante Opens Moscow Office and Successfully Completes First Centralized Ratings Assessment
8. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
9. Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc.
10. Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.
11. Phonak Successfully Hosts Hearing Care for Adults 2009 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  Celsion Corporation (NASDAQ: CLSN ... a conference call to discuss its second quarter ... its development programs for ThermoDox®, its proprietary heat-activated ... technology platforms, TheraPlas™ and TheraSilence™, in immunotherapy and ... August 10, 2015. To participate in the call, ...
(Date:8/3/2015)... , Aug. 3, 2015 Immune Pharmaceuticals, Inc. ... Dr. Daniel Teper , will present live at ... 6, 2015 TIME:   11:30AM EDT LINK:    http://tinyurl.com/aug6-pre-imnp ... interactive online event where investors are invited to ask ... presentation hall as well as the association,s "virtual trade ...
(Date:8/3/2015)... 2015  Encision Inc. (PK:ECIA), a medical device company ... burns in minimally invasive surgery, today announced financial results ... 30, 2015. The Company posted quarterly net ... of $213 thousand, or $(0.02) per share. These results ... net loss of $202 thousand, or $(0.02) per share, ...
Breaking Medicine Technology:Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015 2Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... announces that a new market research report is ... Outlook for Pharmaceuticals in Central Asia ... for Pharmaceutical Markets in Asia is a unique ... Each report provides individual and highly-detailed analysis of ...
... Reportlinker.com announces that a new market research report ... The Market for Pharmaceuticals in Brazil, Russia, India ... Evaluate the status, opportunities and threats ... China now and in the future. Market forecasts ...
Cached Medicine Technology:Reportlinker Adds The Outlook for Pharmaceuticals in Central Asia 2Reportlinker Adds The Outlook for Pharmaceuticals in Central Asia 3Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China 2Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China 3Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China 4Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China 5
(Date:8/3/2015)... ... August 03, 2015 , ... Results of a comprehensive ... Healthcare Research and Policy Analysis show widespread support for the U.S. Affordable Care ... or strongly agreed that the controversial law passed in 2010 had “more good ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... to Ahjumawi Lava Springs, California’s northernmost and among its least visited State Parks. ... water aquifers, whose main outflow is at Ahjumawi Lava Springs, part of the ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... A ... Pain: Injection of Stem Cells Found to Release Natural Painkiller That Can Last 'For ... in patients. According to the report, the new study showed that harvesting stem cell-rich ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Dignity Health ... Health Arizona General Hospital Emergency Room – Gilbert, opening in August. The new ... this year in the West Valley. , “Dr. Baldwin is an excellent leader ...
(Date:8/3/2015)... ... 2015 , ... Cambia Health Solutions has promoted Scott Powers ... Medicare and Federal Employee Programs (FEP) lines of business. , Government programs ... In this role, Scott is responsible for overseeing the growth, finance and operations ...
Breaking Medicine News(10 mins):Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2
... HealthDay Reporter , MONDAY, Dec. 12 (HealthDay News) -- When ... a pound, Madeline Mann was the world,s smallest surviving baby. ... title of world,s tiniest infant, weighing in at 0.57 pounds. She ... ventilator in the neonatal intensive care unit at Loyola University Medical ...
... University of Georgia and the Mayo Clinic in Arizona have ... model that mimics 90 percent of human breast and pancreatic ... The vaccine, described this week in the early ... of Sciences , reveals a promising new strategy for treating ...
... MONDAY, Dec. 12 (HealthDay News) -- Breast reconstruction is ... mastectomy, according to a new study. Mastectomy is ... of a breast has implications for the psychological, social ... that reconstruction should be offered," Dr. Marissa Howard-McNatt, an ...
... have created a deck of cards with conversation starters ... parents can use to guide their discussions when talking ... Researchers in the Faculty of Medicine & Dentistry at ... on their findings in a recently published paper in ...
... resistance to brain tumor chemotherapy Glioblastoma multiforme ... human brain tumors that originate in the brain. For ... therapy and chemotherapy with temozolomide. However, many GBMs are ... researchers led by Sameer Agnihotri, at the University of ...
... Reporter , MONDAY, Dec. 12 (HealthDay News) -- An advisory panel ... the Ortho Evra birth control patch carries a higher risk of ... be taken off drug store shelves. The panel, which based ... data, voted 19 to 5 that the benefits of Johnson & ...
Cached Medicine News:Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 2Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 3Health News:Scientists develop vaccine that attacks breast cancer in mice 2Health News:Scientists develop vaccine that attacks breast cancer in mice 3Health News:Scientists develop vaccine that attacks breast cancer in mice 4Health News:After Mastectomy, Breast Reconstruction Is Safe for Older Women 2Health News:Researchers develop 'conversation cards' to broach subject of pediatric weight management 2Health News:Researchers develop 'conversation cards' to broach subject of pediatric weight management 3Health News:JCI online early table of contents: Dec. 12, 2011 2Health News:JCI online early table of contents: Dec. 12, 2011 3Health News:JCI online early table of contents: Dec. 12, 2011 4Health News:JCI online early table of contents: Dec. 12, 2011 5Health News:JCI online early table of contents: Dec. 12, 2011 6Health News:JCI online early table of contents: Dec. 12, 2011 7Health News:JCI online early table of contents: Dec. 12, 2011 8Health News:JCI online early table of contents: Dec. 12, 2011 9Health News:FDA Panel Cites Clot Risk From Contraceptive Patch 2
... monitor offers a comprehensive array of features ... pediatric and neonate patients, to magnetic resonance ... is the first MR monitor designed to ... neonate patient monitoring. The new monitor is ...
... specific antigen (PSA) is a serine protease that ... epithelial cells of the acini and ducts. Normal ... 0.1-2.6 ng/mL. Reports have suggested that elevated level ... must useful tumor markers in diagnosis of prostate ...
... in vitro assay for detection of alpha ... is a protein with molecular mass ranging ... concentration in serum is below 9 ng/mL; ... ovarian, testicular and presacral teratocarcinomas, and other ...
The IDS Gamma-B 25-Hydroxy Vitamin D kit is a conventional liquid phase radioimmunoassay intended for the quantitative determination of 25-hydroxy vitamin D (25-OHD) and other hydroxylated metabolite...
Medicine Products: